PHARMACOKINETICS, TISSUE DISTRIBUTION, AND TOXICITY OF FREE AND LIPOSOMAL AMPHOTERICIN-B IN DIABETIC RATS

被引:72
作者
WASAN, KM
VADIEI, K
LOPEZBERESTEIN, G
LUKE, DR
机构
[1] UNIV HOUSTON,DEPT PHARMACEUT,HOUSTON,TX 77004
[2] UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,IMMUNOBIOL & DRUG CARRIER SECT,HOUSTON,TX 77030
关键词
D O I
10.1093/infdis/161.3.562
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The pharmacokinetics, tissue distribution, and toxicity of free amphotericin B (free AmB)or amphotericin Bencapsulated in liposomes(L-AmB) werecharacterized in experimental diabetic rats and compared with data obtained from nondiabetic rats. After 7 days of insulin-controlled diabetes or saline, each rat was administered a single intravenous bolus dose of free AmB or L-AmB (0.8mg/kg body weight). Bloodsamples wereobtained beforeadministration and serially thereafter for the assessment of serum pharmacokinetics, nephrotoxicity, and biochemical parameters. Beforedrug treatment, diabetic rats demonstrated marked increases in serum cholesterol and triglyceride levels compared with levelsin nondiabetic rats. A significant increase in serum creatinine levels was observed in nondiabetic rats given free AmB but not in other groups. Whereas AmB pharmacokinetics were significantly altered in diabeticrats administered freeAmB, no kinetic differences were found between groups givenL-AmB. Renal AmB levels we remarkedly increased in nondiabetic rats given freeAmBcompared with those in all other groups. Furthermore, significantly greater concentrations of free AmB were found in lung tissue of rats administered L-AmB independent of disease state. Hepatic levelsof AmB were reduced in diabetic rats administered freeAmB.The disposition and nephrotoxicity of L-AmB were independent of vascular lipid composition. © 1990, University of Chicago. All rights reserved.
引用
收藏
页码:562 / 566
页数:5
相关论文
共 19 条
[1]  
BALAZSOVITS JAE, 1989, CANCER CHEMOTH PHARM, V23, P81
[2]   INTERACTION OF PLASMA-PROTEINS AND LIPOPROTEINS WITH AMPHOTERICIN-B [J].
BRAJTBURG, J ;
ELBERG, S ;
BOLARD, J ;
KOBAYASHI, GS ;
LEVY, RA ;
OSTLUND, RE ;
SCHLESSINGER, D ;
MEDOFF, G .
JOURNAL OF INFECTIOUS DISEASES, 1984, 149 (06) :986-997
[3]   PHARMACOKINETICS AND TOXICITY OF CONTINUOUS INFUSION AMPHOTERICIN-B IN CANCER-PATIENTS [J].
CHABOT, GG ;
PAZDUR, R ;
VALERIOTE, FA ;
BAKER, LH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1989, 78 (04) :307-310
[4]   DISTRIBUTION AND ACTIVITY OF AMPHOTERICIN-B IN HUMANS [J].
CHRISTIANSEN, KJ ;
BERNARD, EM ;
GOLD, JWM ;
ARMSTRONG, D .
JOURNAL OF INFECTIOUS DISEASES, 1985, 152 (05) :1037-1043
[5]  
CIPOLLE RJ, 1986, TXB CLIN APPLICATION, P321
[6]   NONENZYMATIC GLYCATION AND ALTERED RENAL STRUCTURE AND FUNCTION IN THE DIABETIC RAT [J].
COPELAND, KR ;
YATSCOFF, RW ;
THLIVERIS, JA ;
MEHTA, A ;
PENNER, B .
KIDNEY INTERNATIONAL, 1987, 32 (05) :664-670
[7]   EFFECTS OF ELEVATION OF SERUM-CHOLESTEROL AND ADMINISTRATION OF AMPHOTERICIN-B COMPLEXED TO LIPOPROTEINS ON AMPHOTERICIN B-INDUCED TOXICITY IN RABBITS [J].
KOLDIN, MH ;
KOBAYASHI, GS ;
BRAJTBURG, J ;
MEDOFF, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (01) :144-145
[8]   PREDISPOSITION TO HYPERTENSION AND SUSCEPTIBILITY TO RENAL-DISEASE IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].
KROLEWSKI, AS ;
CANESSA, M ;
WARRAM, JH ;
LAFFEL, LMB ;
CHRISTLIEB, AR ;
KNOWLER, WC ;
RAND, LI .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (03) :140-145
[9]   LIPID AND LIPOPROTEIN ABNORMALITIES IN DIABETIC-PATIENTS WITH PERIPHERAL VASCULAR-DISEASE [J].
LAAKSO, M ;
PYORALA, K .
ATHEROSCLEROSIS, 1988, 74 (1-2) :55-63
[10]   PATHOLOGY OF MACROVASCULAR DISEASE [J].
LEDET, T ;
HEICKENDORFF, L ;
RASMUSSEN, LM .
BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1988, 2 (02) :391-405